Vaccines (Feb 2023)

Clinical and Serological Follow-Up of 216 Patients with Hematological Malignancies after Vaccination with Pfizer-BioNT162b2 mRNA COVID-19 in a Real-World Study

  • Jean-François Rossi,
  • Emmanuel Bonnet,
  • Christel Castelli,
  • Marion Velensek,
  • Emma Wisniewski,
  • Sophie Heraud,
  • Rania Boustany,
  • Céleste David,
  • Jérôme Dinet,
  • Roland Sicard,
  • Jean-Pierre Daures,
  • Marion Bonifacy,
  • Lysiane Mousset,
  • Emmanuel Goffart

DOI
https://doi.org/10.3390/vaccines11030493
Journal volume & issue
Vol. 11, no. 3
p. 493

Abstract

Read online

Hematological malignancies (HMs) have heterogeneous serological responses after vaccination due to disease or treatment. The aim of this real-world study was to analyze it after Pfizer-BioNT162b2 mRNA vaccination in 216 patients followed up for 1 year. The first 43 patients had an initial follow-up by a telemedicine (TM) system with no major events reported. The anti-spike IgG antibodies were checked 3–4 weeks post-first vaccination and every 3–4 months, by two standard bioassays and a rapid serological test (RST). Vaccine boosts were given when the level was p p = 0.019). The median levels were 228 BAU/mL post-second dose if seroconverted post-first and second, or if seroconverted only post-second dose. A total of 68% of post-second dose negative patients were post-third dose positive. A total of 16% received TC, six with non-severe symptomatic COVID-19 within 15–40 days. Personalized serological follow-up should apply particularly to patients with HMs.

Keywords